Literature DB >> 18081234

Antitumor and antiangiogenic activities of anti-vascular endothelial growth factor hairpin ribozyme in human hepatocellular carcinoma cell cultures and xenografts.

Li-Hua Li1, Zi-Jian Guo, Ling-Ling Yan, Ji-Cheng Yang, Yu-Feng Xie, Wei-Hua Sheng, Zhao-Hui Huang, Xue-Hao Wang.   

Abstract

AIM: To study the effectiveness and mechanisms of anti- human vascular endothelial growth factor (hVEGF) hairpin ribozyme on angiogenesis, oncogenicity and tumor growth in a hepatocarcinoma cell line and a xenografted model.
METHODS: The artificial anti-hVEGF hairpin ribozyme was transfected into hepatocarcinoma cell line SMMC-7,721 and, subsequently, polymerase chain reaction (PCR) and reverse transcription polymerase chain reaction (RT-PCR) were performed to confirm the ribozyme gene integration and transcription. To determine the effects of ribozyme ,VEGF expression was detected by semiquantitative RT-PCR and enzyme liked immunosorbent assay (ELISA). MTT assay was carried out to measure the cell proliferation. Furthermore,the transfected and control cells were inoculated into nude mice respectively, the growth of cells in nude mice and angiogenesis were observed.
RESULTS: VEGF expression was down-regulated sharply by ribozyme in transfected SMMC-7,721 cells and xenografted tumor. Compared to the control group, the transfected cells grew slower in cell cultures and xenografts, and the xenograft formation was delayed as well. In addition, the microvessel density of the xenografted tumor was obviously declined in the transfected group. As demonstrated by microscopy,reduction of VEGF production induced by ribozyme resulted in a significantly higher cell differentiation and less proliferation vigor in xenografted tumor.
CONCLUSION: Anti-hVEGF hairpin ribozyme can effectively inhibit VEGF expression and growth of hepatocarcinoma in vitro and in vivo. VEGF is functionally related to cell proliferation, differentiation and tumori-genesis in hepatocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18081234      PMCID: PMC4205464          DOI: 10.3748/wjg.v13.i47.6425

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  34 in total

1.  Human small cell lung cancer cells express functional VEGF receptors, VEGFR-2 and VEGFR-3.

Authors:  Sachie Tanno; Yoshinobu Ohsaki; Kyoko Nakanishi; Eri Toyoshima; Kenjiro Kikuchi
Journal:  Lung Cancer       Date:  2004-10       Impact factor: 5.705

2.  Ribozyme-mediated selective killing of cancer cells expressing carcinoembryonic antigen RNA by targeted trans-splicing.

Authors:  Heung-Su Jung; Seong-Wook Lee
Journal:  Biochem Biophys Res Commun       Date:  2006-08-23       Impact factor: 3.575

3.  Prognostic significance of vascular endothelial growth factor expression in clear cell renal cell carcinoma.

Authors:  Gordana Djordjevic; Vladimir Mozetic; Danijela Vrdoljak Mozetic; Vanja Licul; Koviljka Matusan Ilijas; Elvira Mustac; Romano Oguic; Zeljko Fuckar; Nives Jonjic
Journal:  Pathol Res Pract       Date:  2007       Impact factor: 3.250

Review 4.  Controlled, targeted, intracellular expression of ribozymes: progress and problems.

Authors:  J J Rossi
Journal:  Trends Biotechnol       Date:  1995-08       Impact factor: 19.536

5.  Recurrence or metastasis of HCC:predictors, early detection and experimental antiangiogenic therapy.

Authors:  Yang-Fu Jiang; Zhi-Hua Yang; Jin-Qun Hu
Journal:  World J Gastroenterol       Date:  2000-02       Impact factor: 5.742

6.  Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors.

Authors:  R Masood; J Cai; T Zheng; D L Smith; D R Hinton; P S Gill
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

Review 7.  Hepatitis B virus genotypes and hepatocellular carcinoma in Japan.

Authors:  Etsuro Orito; Masashi Mizokami
Journal:  Intervirology       Date:  2003       Impact factor: 1.763

8.  Microvessel density and expression of vascular endothelial growth factor and its receptors in diffuse large B-cell lymphoma subtypes.

Authors:  Dita Gratzinger; Shuchun Zhao; Robert J Marinelli; Amy V Kapp; Robert J Tibshirani; Anne S Hammer; Stephen Hamilton-Dutoit; Yasodha Natkunam
Journal:  Am J Pathol       Date:  2007-04       Impact factor: 4.307

9.  Ribozyme-targeting procathepsin D and its effect on invasion and growth of breast cancer cells: an implication in breast cancer therapy.

Authors:  Aruna Vashishta; Sujata Saraswat Ohri; Mary Proctor; Martin Fusek; Vaclav Vetvicka
Journal:  Int J Oncol       Date:  2007-05       Impact factor: 5.650

10.  [Experimental study of anti-VEGF hairpin ribozyme gene inhibiting expression of VEGF and proliferation of ovarian cancer cells].

Authors:  Rui-lan Yan; Xin-hua Qian; Xiao-yan Xin; Ming Jin; Hong-xiang Hui; De-tang Wang; Jian Wang
Journal:  Ai Zheng       Date:  2002-01
View more
  2 in total

Review 1.  RNA Therapeutic Options to Manage Aberrant Signaling Pathways in Hepatocellular Carcinoma: Dream or Reality?

Authors:  Kurt Sartorius; Samuel O Antwi; Anil Chuturgoon; Lewis R Roberts; Anna Kramvis
Journal:  Front Oncol       Date:  2022-05-04       Impact factor: 5.738

2.  Toward angiogenesis of implanted bio-artificial liver using scaffolds with type I collagen and adipose tissue-derived stem cells.

Authors:  Jae Geun Lee; Seon Young Bak; Ji Hae Nahm; Sang Woo Lee; Seon Ok Min; Kyung Sik Kim
Journal:  Korean J Hepatobiliary Pancreat Surg       Date:  2015-05-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.